JP2018518147A - 脳損傷の検出 - Google Patents

脳損傷の検出 Download PDF

Info

Publication number
JP2018518147A
JP2018518147A JP2017541658A JP2017541658A JP2018518147A JP 2018518147 A JP2018518147 A JP 2018518147A JP 2017541658 A JP2017541658 A JP 2017541658A JP 2017541658 A JP2017541658 A JP 2017541658A JP 2018518147 A JP2018518147 A JP 2018518147A
Authority
JP
Japan
Prior art keywords
patient
mir
brain injury
mirna
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017541658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518147A5 (enExample
Inventor
サージュバーイー・エー・パテル
トーマス・エフ・ラウ
Original Assignee
ザ ユニバーシティー オブ モンタナ
ザ ユニバーシティー オブ モンタナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティー オブ モンタナ, ザ ユニバーシティー オブ モンタナ filed Critical ザ ユニバーシティー オブ モンタナ
Publication of JP2018518147A publication Critical patent/JP2018518147A/ja
Publication of JP2018518147A5 publication Critical patent/JP2018518147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017541658A 2015-03-26 2015-09-22 脳損傷の検出 Pending JP2018518147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/669,454 US9605315B2 (en) 2014-03-26 2015-03-26 Detection of traumatic brain injury
US14/669,454 2015-03-26
PCT/US2015/051518 WO2016153549A1 (en) 2015-03-26 2015-09-22 Detection of brain injury

Publications (2)

Publication Number Publication Date
JP2018518147A true JP2018518147A (ja) 2018-07-12
JP2018518147A5 JP2018518147A5 (enExample) 2018-10-25

Family

ID=56979279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541658A Pending JP2018518147A (ja) 2015-03-26 2015-09-22 脳損傷の検出

Country Status (11)

Country Link
US (3) US9605315B2 (enExample)
EP (1) EP3274008B1 (enExample)
JP (1) JP2018518147A (enExample)
CN (1) CN107427614B (enExample)
AU (2) AU2015387481B2 (enExample)
CA (1) CA2976347A1 (enExample)
CL (1) CL2017002420A1 (enExample)
ES (1) ES3014311T3 (enExample)
IL (1) IL253889A0 (enExample)
SG (1) SG11201707332XA (enExample)
WO (1) WO2016153549A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6211511B2 (ja) 2011-04-18 2017-10-11 ディアミール, エルエルシーDiamir, Llc ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ）
WO2015073972A1 (en) 2013-11-18 2015-05-21 Diamir, Llc METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD)
EP3377074B1 (en) * 2015-11-18 2024-01-03 Dignity Health Methods of diagnosing post traumatic epilepsy
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
US11149313B2 (en) 2016-03-21 2021-10-19 Diamir, Llc Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases
CN108300788B (zh) * 2017-01-13 2021-07-09 中国人民解放军南京军区南京总医院 一种用于检测轻型脑外伤的微小核糖核酸组合及其应用
WO2018175941A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Analysis and prediction of traumatic brain injury and concusion symptoms
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
EP3803416A4 (en) * 2018-05-31 2022-05-18 Amydis, Inc. COMPOSITIONS AND METHODS FOR DETECTING BRAIN TRAUMA
WO2025039033A1 (en) * 2023-08-21 2025-02-27 Glia Diagnostics Pty Ltd Methods and reagents for diagnosis and/or prognosis of traumatic brain injury
CN118314963B (zh) * 2023-11-13 2024-10-29 中国人民解放军空军特色医学中心 一种基于lasso回归的血小板储存损伤风险预测模型及其构建方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533042A (ja) * 2002-06-10 2005-11-04 オクラホマ　メディカル　リサーチ　ファウンデーション 中枢神経系の炎症状態の治療において連結ビス（ポリヒドロキシフェニル）およびそのｏ−アルキル誘導体を使用するための方法
US20140170211A1 (en) * 2012-12-18 2014-06-19 Matthew Bennett Compositions and methods for treating traumatic brain injury
US20150011626A1 (en) * 2012-02-15 2015-01-08 The United States of America, as representive by the Secretary, Department of Health and Human Serv Methods of treating and preventing diseases and disorders of the central nervous system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145209A0 (en) * 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2009132273A2 (en) * 2008-04-25 2009-10-29 Merck & Co., Inc. Microrna biomarkers of tissue injury
HUE040281T2 (hu) * 2009-09-14 2019-03-28 Banyan Biomarkers Inc Autoantitest markerek traumás agysérülés diagnózisára
WO2011149354A1 (en) * 2010-05-28 2011-12-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Mirnas involved in the blood brain barrier function
TW201231671A (en) * 2011-01-28 2012-08-01 Univ Kaohsiung Medical Method and kit for in vitro diagnosis of atherosclerosis
WO2013032962A2 (en) 2011-08-28 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
AU2012308092A1 (en) * 2011-09-13 2014-04-17 Commonwealth Scientific And Industrial Research Organisation Detection of viral infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533042A (ja) * 2002-06-10 2005-11-04 オクラホマ　メディカル　リサーチ　ファウンデーション 中枢神経系の炎症状態の治療において連結ビス（ポリヒドロキシフェニル）およびそのｏ−アルキル誘導体を使用するための方法
US20150011626A1 (en) * 2012-02-15 2015-01-08 The United States of America, as representive by the Secretary, Department of Health and Human Serv Methods of treating and preventing diseases and disorders of the central nervous system
US20140170211A1 (en) * 2012-12-18 2014-06-19 Matthew Bennett Compositions and methods for treating traumatic brain injury

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, VOL.34, NO.4, 2014, P.548-553, JPN6019027837, ISSN: 0004234516 *
J NEUROTRAUMA, 2012, VOL.29, P.1379-1387, JPN6019027835, ISSN: 0004234514 *
PLOS ONE, 2014, VOL.9, ISSUE 11, E112019, P.1-20, JPN6019027834, ISSN: 0004234515 *

Also Published As

Publication number Publication date
AU2021258088A1 (en) 2021-11-25
CN107427614B (zh) 2021-10-15
EP3274008B1 (en) 2024-12-04
US10815529B2 (en) 2020-10-27
US20170268058A1 (en) 2017-09-21
SG11201707332XA (en) 2017-10-30
EP3274008C0 (en) 2024-12-04
ES3014311T3 (en) 2025-04-21
IL253889A0 (en) 2017-10-31
AU2021258088B2 (en) 2024-11-28
WO2016153549A1 (en) 2016-09-29
US9605315B2 (en) 2017-03-28
US20150344954A1 (en) 2015-12-03
EP3274008A1 (en) 2018-01-31
US20190352716A1 (en) 2019-11-21
EP3274008A4 (en) 2018-10-24
US10202649B2 (en) 2019-02-12
CL2017002420A1 (es) 2018-07-13
CA2976347A1 (en) 2016-09-29
CN107427614A (zh) 2017-12-01
AU2015387481B2 (en) 2021-08-05
AU2015387481A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
AU2021258088B2 (en) Detection of brain injury
EP3071712B1 (en) Methods of using mirnas from bodily fluids for detection and monitoring of parkinson's disease (pd)
Mastroeni et al. Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease
Villar-Menéndez et al. Increased striatal adenosine A2A receptor levels is an early event in Parkinson’s disease-related pathology and it is potentially regulated by miR-34b
CN105861712B (zh) 使用来自体液的miRNA来早期检测和监控轻度认知障碍(MCI)和阿尔茨海默病(AD)的方法
Yu et al. Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients
US11149313B2 (en) Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases
US20160199399A1 (en) Methods for predicting drug responsiveness in cancer patients
US20080175924A1 (en) System and Method For Diagnosis of Neuropsychiatric Disorders
AU2022202323B2 (en) Treatment of Rett Syndrome
AU2019270336B2 (en) Methods for predicting drug responsiveness in cancer patients
EP4065714A1 (en) Methods and compositions for neuroprotection
WO2014183110A1 (en) Methods for the detection of brain injury
US20220096431A1 (en) Pharmaceutical composition and method for preventing, treating and diagnosing a neurodegenerative disease
Sachs et al. Acid Stress Increases Gene Expression of Pro-inflammatory Cytokines in 6 Madin Darby Canine Kidney Cells 7

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200317